SITC Session at Society of Surgical Oncology's (SSO) 2026 Annual Meeting

When:  Mar 5, 2026 from 08:55 to 09:55 (MT)

The Society of Surgical Oncology (SSO) and the Surgical Committee of the Society for Immunotherapy of Cancer (SITC) are proud to collaborate on a joint session at SSO's 2026 Annual Meeting. This session will provide an up-to-date overview of immunotherapy in the neoadjuvant setting. Expert faculty will review the biological rationale, key clinical trial data, and translational insights that are shaping surgical decision-making. The discussion will highlight what is currently known, how these approaches are being integrated into practice across disease sites, and the challenges and opportunities for surgical oncologists in multidisciplinary care. SSO's Annual Meeting is taking place March 5-7, 2026 in Phoenix, AZ. 

Neoadjuvant Immunotherapy in Surgical Oncology: Evidence, Experience, and Future Directions

 Thursday, March 5, 2026     8:55 AM – 9:55 AM MST  
 CE: 1

Moderators:

Ajay Maker, MD, FACS - University of California San Francisco
Stephanie Downs-Canner, MD - Memorial Sloan Kettering Cancer Center

Agenda:

  • 8:58 AM - 9:08 AM MST
    Biologic Benefit of Neoadjuvant

    Faculty: Sonia Cohen, MD, PhD – Massachusetts General Hospital/Harvard Medical School

  • 9:08 AM - 9:18 AM MST
    Designing Neoadjuvant IO Trials

    Faculty: Michael C. Lowe, MD, MA – Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University

  • 9:18 AM - 9:28 AM MST
    Neoadjuvant IO in GI Malignancies

    Faculty: John E. Mullinax, MD – Surgical Oncology, Sarcoma Department, Moffitt Cancer Center

  • 9:28 AM - 9:38 AM MST
    Using Pathologic Response and Biomarkers to Inform Adjuvant Therapy

    Faculty: Georgia M. Beasley, MD MHS (she/her/hers) – Duke University Medical Center

  • 9:38 AM - 9:53 AM MST
    Q&A
More information

Location

Phoenix Convention Center West Building
100 N 3rd Street
Phoenix, AZ 85004

Related Content